Equibles does not estimate personal net worth.
Get an email with a short summary when Elicio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELTX alertsElicio Therapeutics, Inc. reported in an 8-K filed June 2, 2023 that Christopher Haqq was appointed Executive Vice President, Head of Research and Development and Chief Medical Officer, effective June 1, 2023. The proxy statement of Elicio Therapeutics, Inc. reports total compensation of $1,078,176 for Christopher Haqq in fiscal 2025, including a base salary of $528,100. Disclosed compensation is on record for 4 fiscal years. Christopher Haqq has spoken on 1 investor event across 1 company, most recently for Elicio Therapeutics, Inc. on June 15, 2026. Elicio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Elicio Therapeutics, Inc. includes Robert Connelly (CEO, Chief Accounting Officer and Board Member), Julian Adams (Chairman), Julian Adams, Ph.D. (Chairman and Board Member) and 7 others.
“At the effective time of the Merger, the Company's board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers”
“As Bob mentioned, although Amplify 7P did not meet its primary endpoint, we believe the study identified a robust signal in completely resected patients that informs future development and provides a clear path forward for ELI-02-7P. Turning to slide three, this slide summarizes what we believe are the key conclusions…”
Proxy statement
Start not stated–present
Last confirmed October 9, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Elicio Therapeutics, Inc. (ELTX) | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $528,100 | $1,078,176 |
| 2024 | Elicio Therapeutics, Inc. (ELTX) | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $507,807 | $926,452 |
| 2023 | Elicio Therapeutics, Inc. (ELTX) | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $488,276 | $673,821 |
| 2022 | Elicio Therapeutics, Inc. (ELTX) | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $465,025 | $1,162,356 |
